Vectorite Biomedical

Vectorite Biomedical FCF per Share

The Free Cash Flow per Share of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is -0.22 TWD. In the previous year, Free Cash Flow per Share was -0.33 TWD — a change of -31.84% (higher).

FCF per Share

-0.22TWD

YoY

-31.84%

Last updated:

Free Cash Flow per Share of Vectorite Biomedical is 2025 -0.22 TWD. Free Cash Flow per Share of Vectorite Biomedical was 2024 -0.33 TWD. It decreases by -31.84% higher compared to the previous year.

The Vectorite Biomedical FCF per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF per Share
Date
FCF per Share
Jan 1, 2018
-3.01 TWD
Jan 1, 2019
-1.59 TWD
Jan 1, 2020
-1.29 TWD
Jan 1, 2021
-1.85 TWD
Jan 1, 2022
0.32 TWD
Jan 1, 2023
-0.08 TWD
Jan 1, 2024
-0.33 TWD
Jan 1, 2025
-0.22 TWD
The Vectorite Biomedical FCF per Share history
YEARFCF per ShareYoY
-0.22TWD-31.84%
-0.33TWD+315.13%
-0.08TWD-125.03%
0.32TWD-117.04%
-1.85TWD+43.69%
-1.29TWD-18.98%
-1.59TWD-47.21%
-3.01TWD-918.90%
0.37TWD-120.52%
-1.79TWD-67.44%
-5.51TWD+381.08%
-1.14TWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

Free Cash Flow per Share of Vectorite Biomedical is -0.22 TWD in 2025.

Free Cash Flow per Share of Vectorite Biomedical changed from -0.33 TWD to -0.22 TWD, representing a -31.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow per Share Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

FCF per share measures the free cash flow allocated to each outstanding share. It is a key metric for assessing shareholder value creation.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Vectorite Biomedical

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Vectorite Biomedical